



August 25, 2022

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Discussions Regarding the Manufacturing and Marketing Of “ARCT-154,” Replicon Vaccine Candidate for COVID-19

Meiji Holdings Co., Ltd. announces that its subsidiary, Meiji Seika Pharma Co., Ltd., is currently discussing with Arcturus Therapeutics Inc.*¹ regarding the manufacturing and marketing of the Replicon Vaccine candidate*² (a potential new class of mRNA vaccine) "ARCT-154" (development code) in Japan. ARCT-154 is being developed by Arcturus Therapeutics Inc. and is potentially effective against SARS-CoV-2 variants including the Omicron variant.

Meiji Seika Pharma Co., Ltd. collaborates with ARCALIS, Inc.*³ the potential collaboration including the establishment of a manufacturing (at the plant in Minamisoma, Fukushima Prefecture) and supply chain for ARCT-154 in Japan as soon as possible.

We will disclose the details promptly after the conclusion of the agreement, if an agreement is reached.

There is no impact on the consolidated financial results for the fiscal year ending March 31, 2023.

*1: Arcturus Therapeutics Inc. is a U.S.-based pharmaceutical company founded in 2013. The company develops a global late-stage clinical vaccines for infectious diseases, and mRNA therapeutics and vaccines for rare diseases of the liver and respiratory tract. (<https://arcturusrx.com/>)

*2: A vaccine in which mRNA encoding an antigen protein is replicated intracellularly after vaccination, resulting in sustained production of the antigen protein. It is expected that the dose of inoculation is small and the effect of the vaccine is long-lasting.

*3: ARCALIS, Inc. develops and manufactures mRNA therapeutics and vaccines as a contract development and manufacturing organization (CDMO). The company decided to build its mRNA manufacturing plant in Minamisoma City, Fukushima Prefecture. The plants is scheduled to complete in 2023. (<https://corp.arcalis.co.jp/en>)

#####